GGrantIndex
← Leaderboards

Elsa R Flores

H. Lee Moffitt Cancer Ctr & Res Inst

Google Scholar ↗PubMed ↗ORCID ↗
$12,484,914
Attributed
$13,551,921
Total exposure
11
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.9M · FY2009–25
$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$23,645,089 · 12

By mechanism

P01$11,763,421 · 5
R35$6,372,149 · 1
R01$3,527,015 · 2
T32$1,600,510 · 1
P30$381,994 · 3

Top collaborators

Most similar at H. Lee Moffitt Cancer Ctr & Res Inst

Same institution · by research overlap

Others in their field

Top investigators on “Tumor”

Research focus

TumorMalignant NeoplasmsIn VivoMouse ModelNeoplasm MetastasisProgramsPathway InteractionsGenesFamilyMetabolismLung AdenocarcinomaProtein IsoformsLaboratoriesMemberMalignant Neoplasm Of LungSamplingTp53 GeneMetabolicCellsComplexRegulationCollaborationsMutantInnovation

Grant awards (47)

Identifying Metabolic Vulnerabilities in Lung Cancer$2,032,950
P01 · FY2025 · CA · contact PI
Project 1$237,173
P01 · FY2025 · CA · contact PI
Administrative Core$103,720
P01 · FY2025 · CA · contact PI
Cancer Biology & Evolution$31,729
P30 · FY2025 · CA · contact PI
Identifying Metabolic Vulnerabilities in Lung Cancer$1,951,918
P01 · FY2024 · CA · contact PI
Project 1$225,316
P01 · FY2024 · CA · contact PI
Administrative Core$98,533
P01 · FY2024 · CA · contact PI
Cancer Biology & Evolution$31,727
P30 · FY2024 · CA · contact PI
Identifying Metabolic Vulnerabilities in Lung Cancer$2,019,244
P01 · FY2023 · CA · contact PI
Project 1$232,431
P01 · FY2023 · CA · contact PI
Integrated Program in Cancer and Data Science$211,392
T32 · FY2023 · CA
Administrative Core$101,646
P01 · FY2023 · CA · contact PI
Cancer Biology & Evolution$31,726
P30 · FY2023 · CA · contact PI
Identifying Metabolic Vulnerabilities in Lung Cancer$2,029,016
P01 · FY2022 · CA · contact PI
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma$901,735
R35 · FY2022 · CA · contact PI
Integrated Program in Cancer and Data Science$441,104
T32 · FY2022 · CA
Project 1$231,996
P01 · FY2022 · CA · contact PI
Cancer Biology & Evolution$162,194
P30 · FY2022 · CA · contact PI
Administrative Core$98,544
P01 · FY2022 · CA · contact PI
Identifying Metabolic Vulnerabilities in Lung Cancer$2,060,040
P01 · FY2021 · CA · contact PI
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma$938,802
R35 · FY2021 · CA · contact PI
Integrated Program in Cancer and Data Science$427,875
T32 · FY2021 · CA
Project 1$237,175
P01 · FY2021 · CA · contact PI
Administrative Core$103,719
P01 · FY2021 · CA · contact PI
Cancer Research Workforce Development in FAIR Artificial Intelligence and Machine Learning$86,337
T32 · FY2021 · CA
Cancer Biology & Evolution$60,058
P30 · FY2021 · CA · contact PI
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma$921,602
R35 · FY2020 · CA · contact PI
Integrated Program in Cancer and Data Science$294,797
T32 · FY2020 · CA
Cancer Biology & Evolution$60,062
P30 · FY2020 · CA · contact PI
Cancer Biology & Evolution$4,498
P30 · FY2020 · CA · contact PI
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma$884,938
R35 · FY2019 · CA · contact PI
Integrated Program in Cancer and Data Science$139,005
T32 · FY2019 · CA
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma$904,242
R35 · FY2018 · CA · contact PI
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma$904,402
R35 · FY2017 · CA · contact PI
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma$816,402
R35 · FY2016 · CA · contact PI
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma$100,026
R35 · FY2016 · CA · contact PI
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer$476,186
R01 · FY2015 · CA · contact PI
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer$425,671
R01 · FY2014 · CA · contact PI
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer$65,898
R01 · FY2014 · CA · contact PI
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer$457,446
R01 · FY2013 · CA · contact PI
Investigating the role of p73 and its isoforms in tumorigenesis and metastasis$291,366
R01 · FY2013 · CA · contact PI
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer$49,881
R01 · FY2013 · CA · contact PI
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer$501,539
R01 · FY2012 · CA · contact PI
Investigating the role of p73 and its isoforms in tumorigenesis and metastasis$309,964
R01 · FY2012 · CA · contact PI
Investigating the role of p73 and its isoforms in tumorigenesis and metastasis$309,964
R01 · FY2011 · CA · contact PI
Investigating the role of p73 and its isoforms in tumorigenesis and metastasis$319,550
R01 · FY2010 · CA · contact PI
Investigating the role of p73 and its isoforms in tumorigenesis and metastasis$319,550
R01 · FY2009 · CA · contact PI